Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by PGGM Investments

PGGM Investments lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 36,029 shares of the biopharmaceutical company’s stock after selling 20,613 shares during the period. PGGM Investments’ holdings in Regeneron Pharmaceuticals were worth $31,644,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Headlands Technologies LLC increased its holdings in shares of Regeneron Pharmaceuticals by 24,760.0% in the fourth quarter. Headlands Technologies LLC now owns 1,243 shares of the biopharmaceutical company’s stock valued at $1,092,000 after buying an additional 1,238 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its stake in Regeneron Pharmaceuticals by 5.9% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 89,055 shares of the biopharmaceutical company’s stock valued at $78,216,000 after purchasing an additional 4,954 shares during the period. Stevens Capital Management LP acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $367,000. Abbrea Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $235,000. Finally, Syon Capital LLC raised its stake in Regeneron Pharmaceuticals by 27.4% during the 4th quarter. Syon Capital LLC now owns 782 shares of the biopharmaceutical company’s stock valued at $687,000 after purchasing an additional 168 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on REGN shares. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group boosted their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Finally, Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Stock Down 0.8 %

NASDAQ:REGN traded down $7.48 during trading hours on Friday, reaching $883.20. The company’s stock had a trading volume of 505,652 shares, compared to its average volume of 431,865. The company has a market cap of $96.94 billion, a price-to-earnings ratio of 25.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The business’s 50-day moving average is $948.00 and its 200-day moving average is $893.63. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the prior year, the company posted $10.96 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders sold a total of 11,022 shares of company stock valued at $10,552,991 in the last quarter. Insiders own 8.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.